Chronic Schizophrenia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic schizophrenia. 16 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
16
Active US patents
70/100
Avg vulnerability
Annual revenue covered

Originators in Chronic Schizophrenia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Acacia 16 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic schizophrenia. Each bar = one year. Y-axis scaled to peak year (8 patents).

8
31
2
34
6
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Barhemsys
AMISULPRIDE
Acacia 16 70 2031-03-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12194022 Barhemsys method of use 81 2031-03-10
12194022 Barhemsys method of use 81 2031-03-10
9889118 Barhemsys method of use 76 2031-03-10
9545426 Barhemsys method of use 76 2031-03-10
12329740 Barhemsys method of use 75 2038-02-09
12329740 Barhemsys method of use 75 2038-02-09
12005042 Barhemsys method of use 75 2038-02-09
12005042 Barhemsys method of use 75 2038-02-09
9084765 Barhemsys method of use 70 2034-02-26
11357753 Barhemsys method of use 70 2038-02-09

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10525033 Barhemsys formulation 48 2031-03-10
10525033 Barhemsys formulation 56 2031-03-10
9084765 Barhemsys method of use 62 2034-02-26
9545426 Barhemsys method of use 68 2031-03-10
9889118 Barhemsys method of use 68 2031-03-10
11357753 Barhemsys method of use 70 2038-02-09
11357753 Barhemsys method of use 70 2038-02-09
9084765 Barhemsys method of use 70 2034-02-26
12329740 Barhemsys method of use 75 2038-02-09
12329740 Barhemsys method of use 75 2038-02-09

Related